A Look Ahead: Zymeworks's Earnings Forecast
Benzinga Insights 8 months ago
Earnings
Zymeworks (NASDAQ:ZYME) is preparing to release its quarterly earnings on Monday, 2026-03-02. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Zymeworks to report an earnings per share (EPS) of $-0.33.
Anticipation surrounds Zymeworks's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Performance in Previous Earnings
In the previous earnings release, the company beat EPS by $0.05, leading to a 8.04% drop in the share price the following trading session.
Here's a look at Zymeworks's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.31 | -0.48 | -0.45 | -0.09 |
| EPS Actual | -0.26 | 0.03 | -0.30 | -0.31 |
| Price Change % | -8.04 | -1.15 | -0.13 | -7.97 |
Market Performance of Zymeworks's Stock
Shares of Zymeworks were trading at $23.81 as of February 26. Over the last 52-week period, shares are up 81.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Discovering Zymeworks: A Closer Look
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Understanding the Numbers: Zymeworks's Finances
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Zymeworks's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 72.59% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Zymeworks's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -70.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Zymeworks's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.99% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -4.87%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Zymeworks adopts a prudent financial strategy, indicating a balanced approach to debt management.
To track all earnings releases for Zymeworks visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.